Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis

Mairead K. Heavey,Anthony Hazelton,Yuyan Wang,Mitzy Garner,Aaron C. Anselmo,Janelle C. Arthur,Juliane Nguyen

DOI: https://doi.org/10.1038/s41467-024-48128-0

IF: 16.6

2024-05-07

Nature Communications

Abstract:Probiotic and engineered microbe-based therapeutics are an emerging class of pharmaceutical agents. They represent a promising strategy for treating various chronic and inflammatory conditions by interacting with the host immune system and/or delivering therapeutic molecules. Here, we engineered a targeted probiotic yeast platform wherein Saccharomyces boulardii is designed to bind to abundant extracellular matrix proteins found within inflammatory lesions of the gastrointestinal tract through tunable antibody surface display. This approach enabled an additional 24–48 h of probiotic gut residence time compared to controls and 100-fold increased probiotic concentrations within the colon in preclinical models of ulcerative colitis in female mice. As a result, pharmacodynamic parameters including colon length, colonic cytokine expression profiles, and histological inflammation scores were robustly improved and restored back to healthy levels. Overall, these studies highlight the potential for targeted microbial therapeutics as a potential oral dosage form for the treatment of inflammatory bowel diseases.

multidisciplinary sciences

What problem does this paper attempt to address?

The paper aims to address several key issues in the treatment of Inflammatory Bowel Disease (IBD). Specifically:

1. **Prolonging the retention time of probiotics in the gut**: The research team genetically engineered Saccharomyces boulardii to bind to extracellular matrix proteins abundant in inflamed areas of the gut, thereby extending its retention time in the gut.

2. **Enhancing therapeutic efficacy**: By increasing the concentration of probiotics in the colon, the pharmacokinetic parameters in a mouse model of ulcerative colitis were improved, including colon length, colonic cytokine expression profiles, and histological inflammation scores.

3. **Overcoming the limitations of existing therapies**: Many current treatments have severe side effects and cannot target inflamed areas of the gut. Additionally, these drugs often require administration via subcutaneous injection or hospital infusion, whereas the engineered probiotics can be administered orally, making it more convenient for patients.

In summary, the goal of this research is to develop a novel oral probiotic delivery system to improve the treatment of Inflammatory Bowel Disease and reduce side effects.